Literature DB >> 2462151

A protective monoclonal antibody that reacts with a novel antigen of pneumococcal teichoic acid.

L S McDaniel1, W D Waltman, B Gray, D E Briles.   

Abstract

D3114/63 is a hybridoma cell line producing a monoclonal antibody that appears to recognize a common antigenic determinant associated with the teichoic acids of Streptococcus pneumoniae. This hybridoma was produced in a fusion of splenic lymphocytes from an X-linked immunodeficient (xid) male (CBA/NxBALB/c)F1 mouse hyperimmunized with a heat-killed type 6A strain EF-3114. Treatment of EF-3114 with periodate, but not with protease, destroyed its ability to bind D3114/63. The specificity of D3114/63 for teichoic acids was suggested by the ability of both C-polysaccharide and F-antigen to inhibit its binding to EF-3114. Inhibition studies indicated that D3114/63 does not bind the PC determinant of teichoic acids. As in the case with anti-PC antibodies, the presence of an intact pneumococcal capsule significantly reduced the binding of D3114/63 to viable pneumococci. By means of a colony immunoblot procedure, it was determined that D3114/63 bound to all 97 pneumococcal strains tested including representatives of 24 different serotypes. Both D3114/63 and anti-PC antibodies were able to detect pneumococcal antigen in spinal fluids of 3 out of 4 patients with pneumococcal meningitis. D3114/63 protected mice from fatal infection with type 3 strain WU2 pneumococci but not from type 5 strain DBL5 or type 6A strain EF-3114.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2462151     DOI: 10.1016/0882-4010(87)90058-1

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  13 in total

1.  Acquired, but not innate, immune responses to Streptococcus pneumoniae are compromised by neutralization of CD40L.

Authors:  Y i Hwang; M H Nahm; D E Briles; D Thomas; J M Purkerson
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity.

Authors:  Fan Zhang; Ying-Jie Lu; Richard Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

Review 3.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

4.  Cross-reactive monoclonal antibodies for diagnosis of pneumococcal meningitis.

Authors:  W D Waltman; B Gray; L S McDaniel; D E Briles
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

5.  Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine.

Authors:  Kristin L Moffitt; Puja Yadav; Daniel M Weinberger; Porter W Anderson; Richard Malley
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

6.  Opsonic antibodies to Enterococcus faecalis strain 12030 are directed against lipoteichoic acid.

Authors:  Christian Theilacker; Zbigniew Kaczynski; Andrea Kropec; Francesca Fabretti; Tatjana Sange; Otto Holst; Johannes Huebner
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

7.  Mouse antibody to phosphocholine can protect mice from infection with mouse-virulent human isolates of Streptococcus pneumoniae.

Authors:  D E Briles; C Forman; M Crain
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

8.  Penicillin treatment accelerates middle ear inflammation in experimental pneumococcal otitis media.

Authors:  M Kawana; C Kawana; G S Giebink
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

9.  Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization.

Authors:  Tera L McCool; Thomas R Cate; Elaine I Tuomanen; Peter Adrian; Tim J Mitchell; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

10.  PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type.

Authors:  L S McDaniel; J S Sheffield; P Delucchi; D E Briles
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.